2 results
Approved WMOPending
To study the impact of addition of the GAAD score to imaging in patients with chronic liver disease eligible for HCC surveillance.
Approved WMORecruiting
The goal of the fenebrutinib development program in MS is to evaluate the benefits and risks of fenebrutinib treatment across the spectrum of patients with MS. Based on the existing toxicology, pharmacology, and clinical experience with fenebrutinib…